{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rampersad AG"],"funding":["Intramural CDC HHS"],"pagination":["807-814"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6345165"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(5)"],"pubmed_abstract":["<h4>Introduction</h4>Accurate diagnosis of an inhibitor, a neutralizing antibody to infused factor VIII (FVIII), is essential for appropriate management of haemophilia A (HA). Low-titre inhibitors may be difficult to diagnose due to high rates of false-positive inhibitor results in that range. Transient low-titre inhibitors and false-positive inhibitors may be due to the presence of a lupus anticoagulant (LA) or other non-specific antibodies. Fluorescence immunoassay (FLI) to detect antibodies to FVIII is a sensitive method to identify inhibitors in HA. Evaluations of antibody profiles by various groups have demonstrated that haemophilic inhibitors detected by Nijmegen-Bethesda (NBA) and chromogenic Bethesda (CBA) assays correlate with positivity for anti-FVIII immunoglobulin (Ig) G1 and G"],"journal":["Haemophilia : the official journal of the World Federation of Hemophilia"],"pubmed_title":["Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients."],"pmcid":["PMC6345165"],"funding_grant_id":["CC999999"],"pubmed_authors":["Shapiro A","Boylan B","Rampersad AG","Miller CH"],"additional_accession":[]},"is_claimable":false,"name":"Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients.","description":"<h4>Introduction</h4>Accurate diagnosis of an inhibitor, a neutralizing antibody to infused factor VIII (FVIII), is essential for appropriate management of haemophilia A (HA). Low-titre inhibitors may be difficult to diagnose due to high rates of false-positive inhibitor results in that range. Transient low-titre inhibitors and false-positive inhibitors may be due to the presence of a lupus anticoagulant (LA) or other non-specific antibodies. Fluorescence immunoassay (FLI) to detect antibodies to FVIII is a sensitive method to identify inhibitors in HA. Evaluations of antibody profiles by various groups have demonstrated that haemophilic inhibitors detected by Nijmegen-Bethesda (NBA) and chromogenic Bethesda (CBA) assays correlate with positivity for anti-FVIII immunoglobulin (Ig) G1 and G","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Sep","modification":"2025-04-25T23:19:21.067Z","creation":"2019-03-26T22:39:41Z"},"accession":"S-EPMC6345165","cross_references":{"pubmed":["30004159"],"doi":["10.1111/hae.13565"]}}